Catherine M. Szyman Edwards Lifesciences Corp (EW) insider trading activity

Catherine M. Szyman is CVP, Critical Care of Edwards Lifesciences Corp. Currently has a direct ownership of 81,287 shares of EW, which is worth approximately $5.45 Million. The most recent transaction as insider was on Sep 03, 2024, when has been sold 5,530 shares (Common Stock) at a price of $69.96 per share, resulting in proceeds of $386,878. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 81.3K

7.09% 3M change

133.5% 12M change

Total Value Held $5.45 Million

Catherine M. Szyman Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 03 2024	SELL Payment of exercise price or tax liability	$386,878 $69.96 p/Share	5,530 Reduced 6.37%	81,287 Common Stock
Sep 03 2024	BUY Grant, award, or other acquisition	-	10,910 Added 11.16%	86,817 Common Stock
Jul 07 2024	SELL Payment of exercise price or tax liability	$23,818 $92.32 p/Share	258 Reduced 0.34%	75,907 Common Stock
May 11 2024	SELL Payment of exercise price or tax liability	$71,717 $86.72 p/Share	827 Reduced 1.07%	76,165 Common Stock
May 07 2024	SELL Payment of exercise price or tax liability	$51,819 $85.09 p/Share	609 Reduced 0.78%	76,992 Common Stock
May 07 2024	BUY Grant, award, or other acquisition	-	32,025 Added 29.21%	77,601 Common Stock
May 04 2024	SELL Payment of exercise price or tax liability	$293,430 $85.25 p/Share	3,442 Reduced 7.02%	45,576 Common Stock
May 04 2024	BUY Exercise of conversion of derivative security	-	5,796 Added 10.57%	49,018 Common Stock
May 03 2024	SELL Payment of exercise price or tax liability	$40,743 $85.06 p/Share	479 Reduced 1.1%	43,222 Common Stock
Feb 22 2024	BUY Grant, award, or other acquisition	-	8,560 Added 16.48%	43,373 Common Stock
Feb 15 2024	SELL Open market or private sale	$2,311,740 $85.62 p/Share	27,000 Reduced 43.68%	34,813 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	$992,250 $36.75 p/Share	27,000 Added 30.4%	61,813 Common Stock
Feb 13 2024	SELL Open market or private sale	$1,729,199 $86.46 p/Share	20,000 Reduced 36.49%	34,813 Common Stock
Feb 13 2024	BUY Exercise of conversion of derivative security	$735,000 $36.75 p/Share	20,000 Added 26.73%	54,813 Common Stock
Oct 10 2023	SELL Open market or private sale	$363,400 $72.68 p/Share	5,000 Reduced 12.56%	34,813 Common Stock
Oct 10 2023	BUY Exercise of conversion of derivative security	$183,750 $36.75 p/Share	5,000 Added 11.16%	39,813 Common Stock
Sep 08 2023	SELL Open market or private sale	$380,000 $76.0 p/Share	5,000 Reduced 12.56%	34,813 Common Stock
Sep 08 2023	BUY Exercise of conversion of derivative security	$183,750 $36.75 p/Share	5,000 Added 11.16%	39,813 Common Stock
Aug 09 2023	SELL Open market or private sale	$393,200 $78.64 p/Share	5,000 Reduced 12.56%	34,813 Common Stock
Aug 09 2023	BUY Exercise of conversion of derivative security	$183,750 $36.75 p/Share	5,000 Added 11.16%	39,813 Common Stock
Jul 10 2023	SELL Open market or private sale	$452,600 $90.52 p/Share	5,000 Reduced 12.56%	34,813 Common Stock
Jul 10 2023	BUY Exercise of conversion of derivative security	$183,750 $36.75 p/Share	5,000 Added 11.16%	39,813 Common Stock
Jul 07 2023	SELL Payment of exercise price or tax liability	$22,795 $90.46 p/Share	252 Reduced 0.72%	34,813 Common Stock
Jun 13 2023	SELL Open market or private sale	$429,050 $85.81 p/Share	5,000 Reduced 12.48%	35,055 Common Stock
Jun 13 2023	BUY Exercise of conversion of derivative security	$183,750 $36.75 p/Share	5,000 Added 11.1%	40,055 Common Stock

Also insider at

Outset Medical, Inc. Healthcare

Director

NARI

Inari Medical, Inc. Healthcare

Director

CMS